An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era 

by

Alejandro Pascual-Iglesias

^1,2,†,

Javier Canton

^3,†,

Ana Maria Ortega-Prieto

⁴,

Jose M. Jimenez-Guardeño

^4,* and

Jose Angel Regla-Nava

^5,6,*

¹

The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain

²

Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain

³

International Institute for Defense and Security (CISDE), 41007 Sevilla, Spain

⁴

Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London SE1 9RT, UK

⁵

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

⁶

Department of Microbiology and Pathology, University Center for Health Science (CUCS), University of Guadalajara, Guadalajara 44340, Mexico

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally.

Academic Editor: Theresa Chang

Pathogens 2021, 10(8), 1030; https://doi.org/10.3390/pathogens10081030

Received: 12 July 2021 / Revised: 1 August 2021 / Accepted: 11 August 2021 / Published: 14 August 2021

(This article belongs to the Special Issue Viral Pathogenesis and Immunity)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic all over the world. When the virus was first isolated and its genome was sequenced in the early months of 2020, the efforts to develop a vaccine began. Based on prior well-known knowledge about coronavirus, the SARS-CoV-2 spike (S) protein was selected as the main target. Currently, more than one hundred vaccines are being investigated and several of them are already authorized by medical agencies. This review summarizes and compares the current knowledge about main approaches for vaccine development, focusing on those authorized and specifically their immunogenicity, efficacy preventing severe disease, adverse side effects, protection, and ability to cope with emergent SARS-CoV-2 variants. View Full-Text

Keywords: coronavirus; SARS-CoV-2; COVID-19; vaccine; clinical trial; pandemic

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License 

 

 

 

 

 

 

 

 

 

 

 

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Pascual-Iglesias, A.; Canton, J.; Ortega-Prieto, A.M.; Jimenez-Guardeño, J.M.; Regla-Nava, J.A. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens 2021, 10, 1030. https://doi.org/10.3390/pathogens10081030

AMA Style

Pascual-Iglesias A, Canton J, Ortega-Prieto AM, Jimenez-Guardeño JM, Regla-Nava JA. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens. 2021; 10(8):1030. https://doi.org/10.3390/pathogens10081030

Chicago/Turabian Style

Pascual-Iglesias, Alejandro, Javier Canton, Ana M. Ortega-Prieto, Jose M. Jimenez-Guardeño, and Jose A. Regla-Nava. 2021. "An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era" Pathogens 10, no. 8: 1030. https://doi.org/10.3390/pathogens10081030

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Citations

Crossref

 

5

Scopus

 

3

Web of Science

 

1

PubMed

 

3

PMC

 

3

Google Scholar

 

[click to view]

Article Access Statistics

https://www.mdpi.com/2076-0817/10/8/1030